Study guide

21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

Key Takeaways Explain This Topic AI

Pediatric computerized provider order entry must capture weight in kilograms only, refuse to calculate from a stale or pounds-entered weight, and drive dose-range checking from weight and body surface area, because the kilogram-only standard is the single highest-yield structural defense against the pediatric tenfold error.

Published override rates for interruptive medication alerts commonly range from roughly 50% to over 90%, so decision support must be tiered, reserving hard stops and interruptive alerts for genuinely lethal scenarios and delivering the rest passively.

Closed-loop medication management combines CPOE with decision support, barcode-assisted dispensing, smart pumps with dose error reduction software, barcode medication administration, and bidirectional pump-to-electronic-health-record auto-programming, which removes manual pump keypad entry.

Drug shortages hit pediatrics disproportionately because affected products are often low-margin, low-volume, sterile injectables and the substitute frequently arrives at a different concentration, creating a tenfold error risk at the moment of substitution.

The FDA Drug Shortages Database and the ASHP shortage resource are the two authoritative sources, and ASHP guidelines frame shortage response as detect, assess supply against projected use, identify therapeutic alternatives through P&T, restrict and prioritize, communicate, and document.

Last updated: September 2026

21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

Clinical Informatics and Emergency Preparedness and Drug Shortage Resources are both listed under Practice Management in the BPS Pediatric Pharmacy content outline. They belong together because both are system-level defenses: informatics prevents the error that weight-based dosing invites, and shortage management prevents the error that an unexpected substitution invites.

Why Pediatric Informatics Is a Different Problem

An adult order for "metoprolol 25 mg PO BID" is fully specified. A pediatric order for "metoprolol 1 mg/kg/day divided BID" is a computation whose correctness depends on a stored weight, a unit convention, a rounding rule, and a concentration. Every one of those is a failure point.

The Kilogram-Only Standard

The Institute for Safe Medication Practices and The Joint Commission both call for recording and displaying pediatric weight in kilograms only . Dual units are how a 30-pound toddler receives a dose calculated for 30 kilograms — a 2.2-fold overdose that passes every downstream check because the arithmetic was flawless.

A safe pediatric CPOE configuration:

Accepts and displays kilograms only in every clinical screen, order, label, and flowsheet.

Requires a documented weight before any weight-based order can be signed.

Flags a stale weight — what counts as stale differs by population, with neonates requiring a current daily weight and general pediatrics tolerating a few days.

Shows the calculation on the order : mg/kg/dose, the weight used, and the resulting milligram amount, so a verifier can reproduce it.

Blocks free-text dose entry for high-alert medications.

Dose Range Checking

Dose range checking (DRC) compares a calculated dose against age- and weight-indexed minimum and maximum values, ideally checking four dimensions at once: per dose, per kilogram per dose, per day, and against the adult maximum . It is the electronic implementation of the cap rule.

DRC in pediatrics is harder than in adults because a single drug can have three legitimate dosing schemes at once — gentamicin dosed per kilogram in neonates by post-menstrual age, extended-interval in older children, and synergy dosing in endocarditis. A poorly tuned DRC ruleset that fires on all three trains clinicians to override, which is worse than no rule.

Alert Fatigue and Tiering

Published override rates for interruptive medication-related alerts commonly run from roughly 50% to well over 90% . An alert that is overridden nine times out of ten is not a safety control; it is a click. TIERING CLINICAL DECISION SUPPORT

HARD STOP Cannot be overridden without pharmacy or

(rare) physician-leader authorization.

  • Reserve for lethal events: intrathecal vincristine,
  • concentrated potassium chloride on a nursing unit,

10-fold-above-maximum chemotherapy doses.

INTERRUPTIVE Modal alert requiring a documented reason to proceed.

(uncommon) Reserve for high-severity, high-specificity events:

true contraindicated interactions, allergy with a

documented anaphylaxis history.

PASSIVE In-line display, order-set default, or info button.

(most) Duplicate therapy, moderate interactions, reference

dosing, renal adjustment suggestions.

DESIGNED OUT Best of all: standardized concentrations, pre-built

order sets, default rounding, forcing functions.

No alert is needed for an error that cannot be made.

Governance matters as much as design. High-performing programs measure override rate by rule , retire or re-specify any rule whose override rate exceeds a governance threshold, and require a pharmacist on the decision-support committee.

Standardized Concentrations and the Pump Library

The ASHP Standardize 4 Safety initiative established national standard concentrations for pediatric and neonatal continuous infusions. From an informatics standpoint, standardization is what makes a drug library possible at all: a single tested library entry per clinical care area can only exist if every patient receives the same concentration. It also enables batch preparation , reducing both waste and turnaround time. The internal mechanics of the pump library — clinical care areas, soft versus hard limits, override auditing, and the abandonment of patient-specific concentration calculation — are covered in the smart infusion pump section of the medication safety chapter.

  • Closed-Loop Medication Management ORDER CPOE + clinical decision support + dose range checking
  • |
  • VERIFY Pharmacist review with pediatric-specific rules
  • |
  • PREPARE Barcode-assisted sterile compounding; gravimetric or
  • image-capture verification of the compounded product
  • |
  • DISPENSE Barcoded, patient-specific, unit-of-use label
  • |
  • ADMINISTER Barcode medication administration (BCMA): right
  • patient, right drug, right dose, right route, right time
  • |
  • INFUSE Smart pump with dose error reduction software; ideally
  • AUTO-PROGRAMMED from the EHR order, so no one types a
  • rate into a keypad
  • |
  • MONITOR Documentation flows back to the record; pump
  • compliance and override reports drive library updates

Two informatics facts worth holding: auto-programming (bidirectional pump-EHR interoperability) removes manual keypad entry, which is the last remaining place a decimal point can be misplaced by hand; and smart pump compliance reporting — the proportion of infusions started from the drug library rather than in basic infusion mode — is the metric that tells you whether the safety software is actually being used.

  • Drug Shortage Management
  • Why Shortages Are Worse in Pediatrics

Shortage-prone products are disproportionately older, low-margin, low-volume sterile injectables from a small number of manufacturing lines — precisely the profile of many pediatric staples. The pediatric consequences compound:

No alternative dosage form. An adult can take an oral substitute; a 900 g neonate on continuous infusion frequently cannot.

Concentration substitution is a tenfold-error generator. When the familiar 1 mg/mL product is replaced by a 10 mg/mL import, every stored order, pump library entry, and nursing habit becomes wrong on the same day.

Imported products obtained under FDA temporary importation carry foreign labeling , different concentrations and units, and no barcode that scans in the local system.

Compounding burden shifts to the pharmacy , bringing USP <795> and <797> obligations, stability uncertainty, and beyond-use-date limits.

Excipient substitution. The replacement product may contain benzyl alcohol, propylene glycol, or ethanol in amounts that are irrelevant in adults and toxic in neonates.

Authoritative Sources

FDA Drug Shortages Database — the regulatory source of record, reporting current shortages, resolved shortages, and reason categories. Manufacturers are required to notify the FDA of anticipated interruptions.

ASHP Drug Shortages Resource Center — maintained with the University of Utah Drug Information Service; typically more clinically actionable, with management suggestions and alternative-agent guidance.

ASHP Guidelines on Managing Drug Product Shortages — the framework below.

Professional bodies such as the Pediatric Pharmacy Association issue pediatric-specific shortage guidance.

The Response Framework

Step Action Pediatric specifics

1. Detect & verify Confirm with the wholesaler and the FDA/ASHP listings; establish expected duration Do not act on a single backorder message

2. Assess Quantify on-hand inventory against projected use by indication Pull actual pediatric utilization, not adult-weighted estimates

3. Identify alternatives P&T or a designated shortage team selects therapeutic alternatives Confirm the alternative has pediatric dosing, an age-appropriate form, and an acceptable excipient profile

4. Restrict & prioritize Reserve remaining supply for indications with no substitute Neonates and patients with no enteral route usually rank first

5. Operationalize Update the formulary, order sets, CPOE dose rules, smart pump library, automated dispensing cabinets, and labels before the substitute reaches the floor This is the step that prevents the concentration-change tenfold error

6. Communicate Notify prescribers, nursing, and families with the specific change, not a general shortage notice Name the old and new concentrations explicitly

7. Document & review Record decisions, adverse outcomes, and resolution Feeds the next shortage and any regulatory reporting

Warning

The most dangerous day of a shortage is the day the substitute arrives. Standard concentration changes, imported foreign-labeled products, and unfamiliar vial sizes converge while clinical urgency is highest. Build the pump library entry, update the order sets, and brief nursing before the product is released to patient care areas.

Emergency Preparedness

Disaster and mass-casualty planning fails children by default, because caches and protocols are built around adult unit doses.

Strategic National Stockpile and CHEMPACK caches contain nerve-agent antidotes; pediatric autoinjector doses of atropine and pralidoxime must be identified in advance, and pediatric dosing guidance kept with the cache.

Potassium iodide for radiologic events is dosed by age, and thyroid blockade is most valuable in children because of their much higher radiation-induced thyroid cancer risk.

Pediatric surge planning must account for weight-based dosing at scale, availability of oral liquids, and the fact that children arriving unaccompanied may have no weight, no history, and no identifier.

Maintain downtime procedures : a paper weight-based dosing reference and pre-calculated code-dose sheets for when CPOE, the pump library, and barcode scanning are all unavailable.

Practice Pearls & BCPPS Exam Traps

Exam Trap 1: The correct answer to "how do we stop the pounds-to-kilograms error?" is a structural one — kilogram-only capture and display — not another alert.

Exam Trap 2: More alerts is not the safety answer. An option proposing a new interruptive alert to solve a problem already generating high override rates is almost always wrong; tiering, standardization, or a forcing function is the better answer.

Exam Trap 3: During a shortage, the first operational task once an alternative is chosen is to update the pump library, order sets, and dose rules before the product is dispensed — not to email a notice and hope.

Board Rule: Any shortage substitution that changes a concentration requires an explicit, documented change bundle: CPOE dose rule, smart pump entry, automated dispensing cabinet configuration, label, and nursing communication. Changing one and not the others is how a tenfold error reaches a patient.